Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Pivotal Study Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Study Recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

May 10, 2022

Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia

Apr 26, 2022

Cellectar Biosciences Announces Key Commercial Team Appointments

Apr 12, 2022

Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update

Mar 21, 2022

Cellectar to Participate at Upcoming Banking Conferences

Mar 10, 2022

Cellectar Biosciences Announces Executive Leadership Changes

Feb 23, 2022

Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference

Jan 4, 2022

Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition

Dec 13, 2021

Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

Dec 8, 2021

Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

Nov 16, 2021
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...29
© 2022 Cellectar Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Q&A